MedTrace Logo

Nitride-Based Raman Biochip for Lung Cancer Diagnosis and Monitoring

NCT07755020 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2026-08-10

No results posted yet for this study

Summary

This prospective, multicenter observational study aims to evaluate the diagnostic and clinical monitoring performance of a nitride-based Raman biochip in participants with and without lung cancer. Peripheral blood samples will be collected and analyzed using the Raman biochip to characterize molecular spectral patterns and assess their association with the current standard diagnosis of lung cancer.

The study plans to enroll 2,000 participants with pathologically confirmed lung cancer and 1,000 participants without lung cancer. Diagnostic performance will be evaluated using measures including sensitivity, specificity, positive predictive value, negative predictive value, and receiver operating characteristic curve analysis. Exploratory analyses will assess performance according to lung cancer histological subtype, disease stage, and longitudinal clinical status.

Conditions

  • Lung Cancer (Diagnosis)
  • Lung Neoplasms

Sponsors & Collaborators

  • Far Eastern Memorial Hospital

    collaborator OTHER

  • Taoyuan General Hospital, Ministry of Health and Welfare

    collaborator OTHER_GOV

  • Taichung Veterans General Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-04
Primary Completion
2032-12-31
Completion
2032-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07755020 on ClinicalTrials.gov